Application of Gene Expression Profiling for Validating Models of Human Breast Cancer

Abstract

While classical histopathologic approaches are invaluable in classifying tumors and understanding aspects of cellular interactions, genomic approaches provide a means to molecularly dissect tumorigenesis. The relationship of gene expression to the development of neoplasia remains an area of intensive research. With the advent of large-scale genomic platforms, alterations in gene expression can be related to the morphological development of cancer. The feasibility of using large-scale genomic analysis platforms has dramatically changed the landscape of biological sciences, as cellular processes must be considered in the context of complex networks. Alterations in gene expression must now be understood in a systems approach in which the relationships between genes expression changes are studied by considering the interplay of multiple regulatory networks. Ultimately, such changes must be understood at the protein level. We have begun to apply this technology to determine changes in gene expression that differentiate various types of mammary cancers that arise in mouse models that have been initiated by different genetic alterations. Ultimately, a molecular catalogue of similarities and differences between rodent and human tumors can be created which will serve to validate or credential particular models for specific experimental purposes, such as preclinical testing. These approaches have led to new insights into molecular pathways involved in oncogenesis, new classifications of human breast cancer, and the identification of new genes that may be relevant to understanding and treating human cancer.

Keywords

Microarray gene expression profiling transgenic mice mammary cancer oncogenes animal models.

References

Allred, D.C.

Clark, G.M.

Elledge, R.

Fuqua, S.A.

Brown, R.W.

, and

Chambness, G.C.

(1993). Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer . J Nat Cancer Inst85, 200—6.

Band, V.

(1998). The role of retinoblastoma and p53 tumor supressor pathways in human mammary epithelial cell immortilization. Inter J Oncol12(3), 499—507.

Berns, E.M.

Foekens, J.A.

van Putten, W.L.

van Staveren, I.L.

Portengen, H.

de Konig, W.C.

, and

Klijn, J.G.

(1992). Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification. J Steroid Biochem Mol Biol43(1—3), 13—9.

Coles, C.

Condie, A.

Chetty, U.

Steel, C.M.

Evans, H.J.

, and

Prosser, J.

(1992). p53 mutations in breast cancer. Cancer Res52, 5291—8.

Courtneidge, S.A.

(1985). Activation of the pp60c-src kinase by middle T antigen binding or by dephosphorylation. Embo J4(6), 1471—7.

Desai, K.V.

Kavanaugh, C.J.

Calvo, A.

, and

Green, J.E.

(2002). Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer. Endocr Relat Cancer9(4), 207—20.

Desai, K.V.

Xiao, N.

Wang, W.

Gangi, L.

Greene, J.

Powell, J.I.

Dickson, R.

Furth, P.

Hunter, K.

Kucherlapati, R.

Simon, R.

Liu, E.T.

, and

Green, J.E.

(2002). Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA99(10), 6967—72.

Guy, C.T.

Cardiff, R.D.

, and

Muller, W.J.

(1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol12(3), 954—61.

Kavanaugh, C.J.

Desai, K.V.

Calvo, A.

Brown, P.H.

Couldrey, C.

Lubet, R.

, and

Green, J.E.

(2002). Pre-clinical applications of transgenic mouse mammary cancer models. Transgenic Res11(6), 617—33.

10.

Li, M.

Hu, J.

Heermeier, K.

Hennighausen, L.

, and

Furth, P.A.

(1996). Expression of a viral oncoprotein during mammary gland development alters cell fate and function: induction of p53-independent apoptosis is followed by impaired milk protein production in surviving cells . Cell Growth Differ7, 3—11.

11.

Liao, D.J.

, and

Dickson, R.B.

(2000). c-Myc in breast cancer. Endocr Relat Cancer7(3), 143—64.

12.

Liu, M.

Von Lintig, F.

Liyanage, M.

Shibata, M.A.

Jorcyk, C.L.

Ried, T.

Boss, G.R.

, and

Green, J.E.

(1998). Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice . Oncogene17, 2403—11.

13.

Ludlow, J.W.

(1993). Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB J7, 866—71.

14.

Maroulakou, I.G.

Anver, M.

Garrett, L.

, and

Green, J.E.

(1994). Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene . Proc Natl Acad Sci USA91, 11236—40.

15.

Mietz, J.A.

Unger, T.

Huibregtse, J.M.

, and

Howley, P.M.

(1992). The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein . EMBO J11, 5013—20.

16.

Muller, W.J.

Sinn, E.

Pattengale, P.K.

Wallace, R.

, and

Leder, P.

(1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell54(1), 105—15.

17.

Rochlitz, C.F.

Scott, G.K.

Dodson, J.M.

Liu, E.

Dollbaum, C.

Smith, H.S.

, and

Benz, C.C.

(1989). Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res49(2), 357—60.

18.

Sinn, E.

Muller, W.

Pattengale, P.

Tepler, I.

Wallace, R.

, and

Leder, P.

(1987). Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell49(4), 465—75.

19.

Sorlie, T.

Perou, C.M.

Tibshirani, R.

Aas, T.

Geisler, S.

Johnsen, H.

Hastie, T.

Eisen, M.B.

van de Rijn, M.

Jeffrey, S.S.

Thorsen, T.

Quist, H.

Matese, J.C.

Brown, P.O.

Botstein, D.

Eystein Lonning, P.

, and

Borresen-Dale, A.L.

(2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications . Proc Natl Acad Sci USA98(19), 10869—74.

20.

Stewart, T.A.

Pattengale, P.K.

, and

Leder, P.

(1984). Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell38(3), 627—37.

21.

Wang, D.Z.

Hammond, V.E.

Abud, H.E.

Bertoncello, I.

McAvoy, J.W.

, and

Bowtell, D.D.

(1997). Mutation in Sos1 dominantly enhances a weak allele of the EGFR, demonstrating a requirement for Sos1 in EGFR signaling and development . Genes Dev11(3), 309—20.